Angelman syndrome is a severe neurodevelopmental disorder caused by deletion or mutation of the maternal allele of the ubiquitin protein ligase E3A (UBE3A) [1] [2] [3] . In neurons, the paternal allele of UBE3A is intact but epigenetically silenced [4] [5] [6] , raising the possibility that Angelman syndrome could be treated by activating this silenced allele to restore functional UBE3A protein 7, 8 . Using an unbiased, high-content screen in primary cortical neurons from mice, we identify twelve topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the paternal Ube3a allele. These drugs included topotecan, irinotecan, etoposide and dexrazoxane (ICRF-187). At nanomolar concentrations, topotecan upregulated catalytically active UBE3A in neurons from maternal Ube3a-null mice. Topotecan concomitantly downregulated expression of the Ube3a antisense transcript that overlaps the paternal copy of Ube3a [9] [10] [11] . These results indicate that topotecan unsilences Ube3a in cis by reducing transcription of an imprinted antisense RNA. When administered in vivo, topotecan unsilenced the paternal Ube3a allele in several regions of the nervous system, including neurons in the hippocampus, neocortex, striatum, cerebellum and spinal cord. Paternal expression of Ube3a remained elevated in a subset of spinal cord neurons for at least 12 weeks after cessation of topotecan treatment, indicating that transient topoisomerase inhibition can have enduring effects on gene expression. Although potential off-target effects remain to be investigated, our findings suggest a therapeutic strategy for reactivating the functional but dormant allele of Ube3a in patients with Angelman syndrome.
No effective therapies exist for Angelman syndrome-an imprinting disorder caused by mutations or deletions in the maternal allele of UBE3A 1-3 . Ube3a is biallelically expressed in most tissues of the body; however, in rodents and humans, most neurons express Ube3a only from the maternally-inherited allele 4, [12] [13] [14] . This unique epigenetic pattern of regulation suggested that it might be possible to unsilence the dormant paternal Ube3a allele in neurons 7, 8 .
To test this possibility, we developed a 384-well high-content screen using primary mouse cortical neurons from Ube3a-yellow fluorescent protein (Ube3a-YFP) knock-in mice 15 , and searched for drug-like molecules that could unsilence the paternal Ube3a-YFP allele (Fig. 1a ). This screen was based on our observation that the imprinting of Ube3a-YFP was maintained in vitro in cultured embryonic cortical neurons. Notably, Ube3a-YFP expression was undetectable (silenced) in cultured neurons when Ube3a-YFP was paternally inherited (Ube3a m1/pYFP ), but was expressed when Ube3a-YFP was maternally inherited (Ube3a mYFP/p1 ) ( Fig. 1b) , with expression increasing from 4 to 10 days in vitro (DIV) (Fig. 1c ). This significant difference between maternal and paternal UBE3A-YFP protein levels provided a large screening window and a Z9-factor score of 0.58 (determined by statistically comparing antibody-enhanced fluorescence intensities and variations between maternal and paternal UBE3A-YFP signals at DIV10), making our high-content platform suitable for unbiased screening.
To perform the screen, we cultured Ube3a m1/pYFP neurons for 7 days and then treated these neurons with compounds (10 mM for 72 h) from several small-molecule libraries ( Fig. 1d and Supplementary Fig. 1 ). In total, we screened 2,306 small molecules in quadruplicate, normalizing values to vehicle-treatment (0.2% dimethyl sulphoxide (DMSO)) (for full methods see Supplementary Methods; for list of all compounds tested see Supplementary Table 1 ). Although methylation and other epigenetic marks are thought to control imprinting of Ube3a 9,16-18 , to our surprise, none of the commonly used compounds that target the epigenome, including chromatin-remodelling drugs and DNA methyltransferase inhibitors, unsilenced the paternal Ube3a-YFP allele. A number of compounds were identified as false positives (grey compounds in Fig. 1d ) due to their intrinsic fluorescence ( Supplementary Fig. 2 ). Our initial screen identified one compound-irinotecan, an FDA-approved topoisomerase type I inhibitor. Irinotecan lacked intrinsic fluorescence and upregulated UBE3A-YFP fluorescence (Fig. 1d , e and Supplementary Fig. 3 ). Irinotecan (10 mM) also upregulated paternal UBE3A-YFP protein ( Fig. 1f ) and endogenous UBE3A protein ( Fig. 1g ) in neuronal cultures from Ube3a m1/pYFP and Ube3a m-/p1 mice (Angelman syndrome model mice 13 ), respectively.
Many topoisomerase I inhibitors, including irinotecan and the related FDA-approved drug topotecan, are derived from the natural product camptothecin (CPT) 19 . To explore structure activity relationships, we tested CPT analogues and other topoisomerase inhibitors ( Fig. 2a and Supplementary Figs 4-10 ). The analogues we tested all lack inherent fluorescence ( Supplementary Fig. 3 ). We found that irinotecan and topotecan upregulated paternal UBE3A-YFP in a dose-and timedependent manner in cultured neurons, with topotecan being 20 times more potent than irinotecan ( Fig. 2a, b and Supplementary Fig. 11 ). In contrast, an inactive analogue of CPT (lactam E ring-CPT) that does not inhibit topoisomerases 20 failed to unsilence the paternal Ube3a-YFP allele ( Fig. 2a and Supplementary Fig. 4 ). Ten additional topoisomerase I inhibitors unsilenced Ube3a-YFP in a dose-dependent manner, including CPT analogues and structurally distinct indenoisoquinolines ( Table 1 and Supplementary Figs 4-7 ). Furthermore, four structurally distinct topoisomerase II inhibitors (etoposide, dexrazoxane, ICRF-193 and amsacrine) also unsilenced the paternal Ube3a-YFP allele ( Table 1 and Supplementary Figs 8-10 ). Thus, our data with 16 topoisomerase inhibitors and one inactive analogue strongly suggest that inhibition of topoisomerase I or II can unsilence the paternal Ube3a allele.
We focused our remaining studies on the topoisomerase I inhibitor topotecan because it is approved for use in humans, it unsilenced Ube3a in the low nanomolar range, and topotecan (300 nM, 72 h) restored UBE3A protein to wild-type levels in cultured neurons from Ube3a m-/p1 mice ( Fig. 2c ).
Many topoisomerase inhibitors, including topotecan, covalently link topoisomerases to DNA, forming stable DNA-enzyme complexes that are separable from free topoisomerase enzymes 19 . Because topotecan inhibits topoisomerase I (TOP1) and Top1 is expressed at high levels in the developing and adult brain 19, 21 , we focused our subsequent analysis on this enzyme. We found that topotecan (300 nM, 72 h) significantly reduced the amount of free TOP1 (Fig. 2d ) in cultured neurons, indicating that topotecan engages its known molecular target at doses that unsilence the paternal Ube3a allele.
UBE3A is a HECT (homology to E6 carboxyl terminus) domain E3 ligase that forms a thioester-ubiquitin intermediate in the presence of E1 and E2 enzymes 22 . This thioester-ubiquitin intermediate is required for HECT domain E3 ligases to mono-and polyubiquitinate their substrates 23 . Interestingly, we noticed that topotecan (300 nM, 72 h) upregulated UBE3A protein in Ube3a m-/p1 cultures along with a higher molecular weight form (resolved after running gels for longer times; Fig. 2e ). This high molecular weight band was also seen in wild-type (Ube3a m1/p1 ) cultures and was lost upon addition of the reducing agent dithiothreitol (DTT) ( Fig. 2e ). These data indicate that the unsilenced paternal copy of UBE3A is catalytically active and competent to form a thioester-ubiquitin intermediate, just like wild-type, maternal-derived UBE3A.
To demonstrate further that UBE3A was catalytically active, we immunoprecipitated UBE3A from cultured wild-type and Ube3a m-/p1 neurons (with or without topotecan), then tested these samples using a gel-mobility shift assay in the presence or absence of the ubiquitin E2 UBCH7 (ref. 24 ). Both wild-type (maternalderived) and topotecan-unsilenced (paternal-derived) UBE3A underwent mobility shifts in the presence of UBCH7 plus free ubiquitin that were abolished by addition of DTT ( Fig. 2f ). This observation indicates the mobility shift was due to addition of covalent ubiquitin, and demonstrates that topotecan can upregulate a functional UBE3A enzyme. Small molecules that were subsequently found to be autofluorescent ( Supplementary  Fig. 2 ) are depicted in grey. The initial screen identified one active compound, irinotecan (red). e, High-magnification view of wells treated with vehicle (0.2% DMSO) or 10 mM irinotecan for 72 h. Neuron density and health is similar in vehicle-and irinotecan-treated cells as evidenced by counterstaining with the nuclear marker DAPI. Scale bar, 100 mm. f, g, Western blots of cultured cortical neurons probed with GFP or UBE3A antibodies, respectively, with or without irinotecan (10 mM for 72 h). Irinot., irinotecan; Veh., vehicle. f, *P , 0.05; twotailed t-test, n 5 3 per group. g, *P , 0.001, one-way ANOVA with Bonferroni post hoc, n 5 7-8 per group. All data are presented as means 6 s.e.m.
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Ube3a is repressed in cis by a large antisense transcript (Ube3a-ATS) that overlaps the paternal allele of Ube3a (Fig. 2g) [9] [10] [11] . Ube3a-ATS is expressed exclusively from the paternal allele as a result of allelespecific methylation of an imprinting centre that overlaps the Ube3a-ATS and Snurf/Snrpn transcription start site 25 . We next sought to determine if topotecan regulated Ube3a expression through changes in Ube3a-ATS expression or altered methylation at the imprinting centre. We found that topotecan upregulated expression of Ube3a in cultured neurons from Ube3a m-/p1 mice while concomitantly downregulating expression of Ube3a-ATS and Snurf/Snrpn (Fig. 2h ). However, topotecan did not alter methylation at the imprinting centre ( Fig. 2i and Supplementary Fig. 12 ). Taken together, these data indicate that topotecan unsilences paternal Ube3a by reducing transcription of a regulatory antisense RNA without appreciably affecting genomic methylation at the imprinting centre.
We then sought to determine if topotecan could unsilence the paternal Ube3a allele in vivo. We first identified a dose that was well tolerated, meaning there were no significant decreases in body weight between the beginning and end of the drug treatments ( Supplementary Fig. 13 ). We then administered topotecan (3.74 mg h 21 ) unilaterally into the lateral ventricle of Ube3a m1/pYFP or Ube3a m2/p1 mice by intracerebroventricular (i.c.v.) infusion for 2 weeks and then killed the mice Supplementary Fig. 12 ). Average methylation status is indicated using a greyscale.
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either immediately or 5 h after drug cessation. Strikingly, topotecan unsilenced paternal Ube3a in the hippocampus, striatum and cerebral cortex of the infused hemisphere, but had only a modest effect on the contralateral (non-infused) hemisphere with no effect in the cerebellum ( Fig. 3a-e and Supplementary Figs 14-15 ). Pharmacokinetic analyses demonstrated that a significant amount of topotecan was detectable in the infused hemisphere immediately after treatment, whereas low levels were present in the contralateral (non-infused) hemisphere and in cerebellum ( Fig. 3a and Supplementary Fig. 14) . However, a higher dose of topotecan (21.6 mg h 21 for 5 days) did unsilence the paternal allele of Ube3a in Purkinje neurons of the cerebellum ( Supplementary Fig. 16 ). No significant difference in topotecan levels was detected in blood between drug-and vehicle-treated mice (data not shown). Topotecan concentrations significantly declined five hours after cessation of i.c.v. drug delivery (Fig. 3a) , indicating that topotecan does not persist and is rapidly removed/metabolized in the brain. Taken together, these pharmacokinetic and pharmacodynamic data indicate that the degree to which topotecan unsilences the paternal Ube3a allele is directly correlated with drug concentrations in the brain. Moreover, our data indicate topotecan has the potential to unsilence the paternal Ube3a allele throughout the nervous system. Genomic imprinting is thought to be established only during prescribed germline and embryonic periods of development and imprinted genes typically remain epigenetically regulated throughout life 26 . Thus, we next sought to determine if topotecan had transient or long-lasting effects on paternal Ube3a expression. To test this possibility, we turned to an intrathecal (i.t.) delivery protocol (Fig. 3f ) because topotecan ( Fig. 3g ) and irinotecan (not shown) unsilenced paternal Ube3a in a sparse population of lumbar spinal neurons, allowing us to quantify all UBE3A-YFP-positive neurons. Moreover, i.t. delivery has been used to deliver topotecan to the brain in humans 27 . We found that topotecan (50 nmol in 5 ml; i.t. once daily, for 10 out of 14 days) was well tolerated ( Supplementary Fig. 13 ) and significantly increased the number of paternal UBE3A-YFP-positive cells in the lumbar spinal cord of mice (Fig. 3g, h and Supplementary Fig. 17a ). The vast majority (.93%) of these UBE3A-YFP-positive cells were NeuN 1 neurons (Supplementary Fig. 17a, b) , indicating topotecan primarily unsilences Ube3a in neurons in vivo. Moreover, the unsilenced paternal UBE3A-YFP protein was expressed at levels comparable to maternal UBE3A-YFP controls ( Supplementary Fig. 17c ). Remarkably, the number of UBE3A-YFP-positive spinal cord neurons remained elevated 12 weeks after cessation of drug treatment (Fig. 3g, h) , much longer than the elimination of topotecan from tissue (Fig. 3a) . These results indicate that topotecan can enduringly unsilence paternal Ube3a in a subset of spinal neurons and indicate that a single course of drug treatment has the capacity to permanently modify expression of Ube3a. 
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In conclusion, we found that topoisomerase inhibitors can unsilence the paternal allele of Ube3a and that the paternally-derived protein is functional. These findings suggest that topoisomerase inhibitors have the potential to rescue the molecular, cellular and behavioural deficits associated with loss of UBE3A 7, 13, 28 . Ube3a expression is modestly upregulated in the brain of Top2b knockout mice 29 , providing genetic support that topoisomerases regulate Ube3a expression. We also found that topotecan reduced expression of paternal Snrpn and Ipw, a genomic region whose deletion is associated with Prader-Willi syndrome 7, 17 . To what extent topotecan regulates expression of other genes in the brain, including Igf2r-, Kcnq1-and Gnas-imprinted gene clusters, and whether long-term treatments with topoisomerase inhibitors produce a Prader-Willi-like condition are unknown. However, topotecan and irinotecan are approved for use in patients with cancer, penetrate into the central nervous system, and are well-tolerated when administered chronically to both adult and paediatric patients 27, 30 . As well, patients treated with topoisomerase inhibitors do not display symptoms associated with Prader-Willi syndrome. Ultimately, our study indicates that topoisomerase inhibitors regulate gene expression through a transcriptional mechanism and could be used to treat symptoms associated with Angelman syndrome.
METHODS SUMMARY
All animal procedures were approved by the University of North Carolina at Chapel Hill Animal Care and Use Committee. We used male and female Ube3a-YFP knock-in mice 15 , Ube3a m-/p1 mice 13 and their age-matched, wild-type controls. High-content screening was performed on a BD Pathway 855 system. UBE3A-YFP was detected for drug screening with an anti-GFP antibody (Novus Biologicals, NB600-308; 1:1,000) because intrinsic YFP fluorescence levels were low in cultured neurons and tissue sections. All data are presented as mean 6 s.e.m., with sample sizes (n) shown in figures or stated in the text. Statistical analyses were performed using SigmaPlot 11 (Systat Software). Normality tests (Shapiro-Wilk) and equal variance tests were run and passed (P . 0.05) before parametric statistical analyses were run. curve-fitting models using Graphpad Prism 5.0 (Graphpad Software). The calculated EC 50 values (potencies) and Y-value top plateau (estimated efficacies or E max ) enabled comparative analyses of the relative potency and efficacy of the identified compounds. To control for potential false positive 'hit' compounds, cortical neurons from wild-type mice, which lack Ube3a-YFP, were also treated to determine if 'hit' compounds exhibit inherent fluorescence.
A Z9-factor score was determined to assess the appropriateness of the screening platform by comparing UBE3A-YFP maternal and paternal fluorescence signals at DIV10. This was done by determining the mean cellular UBE3A-YFP fluorescence of .1,200 neurons in quadruplicate wells for both genotypes, which were normalized to age-matched vehicle-treated control wells. The score was calculated using the following formula: Z9 factor 5 1 2 ((3 3 (s.d. maternal UBE3A-YFP 1 s.d. paternal UBE3A-YFP))/(mean maternal UBE3A-YFP -mean paternal UBE3A-YFP). Immunofluorescence staining in central nervous system tissues. For immunocytochemistry in brain tissues, mice were perfused with 4% paraformaldehyde in 0.1 M PBS, post-fixed overnight, and cryoprotected with 20% sucrose in 0.1 M phosphate buffer, pH 7.4 for two days. Sections (60 mm) were collected and permeabilized with 0.3% Triton X-100 in 0.1 M phosphate buffer for 30 min, and blocked by 5% goat serum for 1 h. Sections were incubated with rabbit polyclonal antibody to GFP (1:1,000, Novus Biologicals, NB600-308) at 4 uC overnight and then incubated with Alexa Fluor 488 goat antibody to rabbit IgG and DAPI for 2 h at room temperature. Images were acquired using a Zeiss LSM 510 and 710 confocal microscopes.
For immunocytochemistry in spinal cord, lumbosacral spinal cord (approximately L1 to S2 and inclusive of the area corresponding to intrathecal injection site) was removed from each mouse and immersion-fixed for 8 h in cold 4% paraformaldehyde and 0.1 M phosphate buffer (pH 7.4). After a period of cryoprotection in 30% sucrose in 0.1 M phosphate buffer, each spinal cord was sectioned on a cryostat at 40 mm. Sections to be stained immediately were collected in PBS, sections to be saved for future study were placed in a PBS/ethylene glycol/glycerol solution and stored at 220 uC. Every fourth section was incubated overnight in a mixture containing a chicken IgY to GFP (1:750; Aves Labs, GFP-1020) and a mouse IgG 1 to NeuN (1:250; Millipore, MAB377) and treated the following day with a cocktail containing goat anti-chicken IgY-Alexa 488 (1:200; Invitrogen, A-11039), goat anti-mouse IgG1-Alexa 568 (1:200; Invitrogen, A-21124) and DRAQ5 (1:10,000; Axxora, BOS-889-001). Immunostained sections were mounted from PBS onto SuperFrost Plus Slides (Fisher), which were then air-dried briefly, rehydrated with PBS, and coverslipped with FluoroGel (Electron Microscopy Sciences). For quantification studies, sections were imaged using a Nikon Eclipse 80i with Surveyor mosaic imaging software. For qualitative assessment, sections were imaged as maximal projections on a Zeiss LSM 510. Optical intensity measurement of UBE3A-YFP in brain tissue and cell counting of UBE3A-YFP-positive neurons in spinal cord. For optical intensity measurement in selected brain regions, sections were imaged using a Zeiss LSM 510 confocal microscope. With custom macros created using ImageJ software 33 , optical intensity of UBE3A-YFP was measured in different regions of hippocampus and striatum from vehicle-and topotecan-treated mice. Image intensity levels were normalized to background intensities from appropriate regions in vehicle-treated mice. Brain sections between Bregma 21.22 mm and 22.06 mm were chosen for analysis (n 5 5 sections per mouse for hippocampus and n 5 3-5 sections per mouse for striatum).
For cell counting in spinal cord, we analysed 14 to 18 sections per mouse in segments corresponding to the injection site. Slices were imaged using a Nikon Eclipse 80i microscope equipped with a Qimaging Retiga Exi high-speed CCD camera system and Surveyor mosaic imaging software using a 310 objective. For qualitative purposes, we also imaged selected sections on a Zeiss LSM 510 confocal microscope. Cells were counted manually by individuals blind to the experimental groups from raw (unprocessed) images using ImageJ and Cellprofiler 34 software.
YFP intensity levels from confocal XYZ image stacks were measured using a semi-automated macro with ImageJ. Individual YFP-positive cells were selected by eye, the criteria being the Z plane having the largest area for each cell. Cell regions were defined by intensity thresholding or manual tracing and the average YFP intensity and percent saturation were calculated for each cell. Western blotting. E13.5-E15.5 primary cortical neurons from Ube3a-YFP, Ube3a-deficient or wild-type mice were plated in six-well plates. At DIV7, neurons were treated with drug or 0.1% DMSO for 72 h, and then total protein lysates were obtained by lysis buffer (1% Triton X-100, 5 mM EDTA, 0.15 M NaCl, 10 mM Tris-HCl, pH 7.5, phosphatase inhibitor cocktails 1, protease inhibitor cocktail). To assess UBE3A-YFP or UBE3A protein levels, 7.5 mg of total protein lysates from Ube3a-YFP or Ube3a-deficient neurons were separated by 8% SDS-polyacrylamide gel electrophoresis. Proteins were then transferred to nitrocellulose membranes, and immunoblotting was performed using a rabbit anti-GFP antibody (Novus,
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